Your browser doesn't support javascript.
loading
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen, Päivi; Prien, Olaf; Kähkönen, Marja; Niehues, Michael; Korjamo, Timo; Denner, Karsten; Nykänen, Pirjo; Vuorela, Annamari; Jungmann, Natalia A; von Bühler, Clemens-Jeremias; Koskinen, Mikko; Zurth, Christian; Gieschen, Hille.
Affiliation
  • Taavitsainen P; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Prien O; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Kähkönen M; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Niehues M; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Korjamo T; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Denner K; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Nykänen P; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Vuorela A; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Jungmann NA; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • von Bühler CJ; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Koskinen M; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Zurth C; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.).
  • Gieschen H; Orion Corporation Orion Pharma, Turku, Finland (P.T.); Bayer AG, Berlin, Germany (O.P., M.N., K.D., C.Z., H.G.); Orion Corporation Orion Pharma, Espoo, Finland (M.K., T.K., P.N., A.V., M.K.); and Bayer AG, Wuppertal, Germany (N.A.J., C.-J.v.B.) hille.gieschen@bayer.com.
Drug Metab Dispos ; 49(6): 420-433, 2021 06.
Article in En | MEDLINE | ID: mdl-33785516
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Glucuronides / Cytochrome P-450 CYP3A / Drug Elimination Routes / UDP-Glucuronosyltransferase 1A9 Limits: Adult / Humans / Male Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Glucuronides / Cytochrome P-450 CYP3A / Drug Elimination Routes / UDP-Glucuronosyltransferase 1A9 Limits: Adult / Humans / Male Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2021 Document type: Article Country of publication: